3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Immunoglobulin Light-chain Amyloidosis
5
Paraproteinemias
1
Amyloidosis
1
Alzheimer Disease
1
Interventions
Dexamethasone
12
Bortezomib
9
Lenalidomide
6
Cyclophosphamide
5
isatuximab
3
fludarabine
3
daratumumab
3
Granulocyte Colony-Stimulating Factor
3
pomalidomide
2
filanesib
2
dacetuzumab
2
Tacrolimus
2
Steroids
2
Injections, Subcutaneous
2
Filgrastim
2
Clinical Protocols
2
Calcium Dobesilate
2
Alemtuzumab
2
plerixafor
1
nirogacestat
1
fludarabine phosphate
1
ficlatuzumab
1
birtamimab
1
Zoledronic Acid
1
Whole-Body Irradiation
1
Vorinostat
1
Tissue Banks
1
Thalidomide
1
Stem Cell Transplantation
1
Ranitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Paraproteinemias
×
birtamimab
×
Plasma cell
×
Clear all
NCT02632786
2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2
Completed
129 enrolled
18 charts